J Card Fail. 2016;22:S66 7. J Maddox et al. 137. Breathett K, Jones J, Lum HD, et al. Factors related to physician clinical decision-making for African-American and Hispanic patients: a qualitative meta-synthesis. J Racial Ethn Health Disparities. 2018; 5:1215 29. 138. Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in older adults with cardiovascular dis- ease. J Am Coll Cardiol. 2019;73:2584 95. 139. Yang X, Lupon J, Vidan MT, et al. Impact of frailty on mortality and hospitalization in chronic heart fail- ure: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7:e008251. 140. Pandey A, Kitzman D, Reeves G. Frailty is inter- twined with heart failure: mechanisms, prevalence, prognosis, assessment and management. J Am Coll Cardiol HF. 2019;7:1001 11. 141. Heidenreich PA, Albert NM, Allen LA, et al. Fore- casting the impact of heart failure in the United States: a policy statement from the American Heart Associa- tion. Circ Heart Fail. 2013;6:606 19. 142. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistic 2016 update: a report from the American Heart Association. Circulation. 2016;133:e38 360. 143. Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: ndings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9 20. 144. Hauptman PJ, Goff ZD, Vidic A, et al. Variability in retail pricing of generic drugs for heart failure. JAMA Intern Med. 2017;177:126 8. 145. Perkovic V, Jardine MJ, Neal B, et al. Canagli ozin and renal outcomes in type 2 diabetes and nephropa- thy. N Engl J Med. 2019;380:2295 306. 146. Gaziano TA, Fonarow GC, Claggett B, et al. Cost- effectiveness analysis of sacubitril/valsartan vs ena- lapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1:666 72. 147. 